China / Sinopharm Looks to mRNA Vaccines; Hong Kong Biotech Investment Continues to Boom; Another Big Manufacturing Investment for Lonza
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its own mRNA vaccine; an update on Hong Kong’s biotech investment ecosystem three year…